Claims for Patent: 9,073,993

Summary for Patent: 9,073,993

Title:	CD19 binding agents and uses thereof
Abstract:	This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
Inventor(s):	McDonagh; Charlotte (Waltham, MA), Cerveny; Charles G. (Seattle, WA), Benjamin; Dennis (Redmond, WA), Carter; Paul (Mercer Island, WA)
Assignee:	Seattle Genetics, Inc. (Bothell, WA)
Application Number:	13/530,074
Patent Claims:	1. A method for treating a CD19-associated disorder in a mammalian subject comprising administering an antibody or antigen-binding fragment that specifically binds to human CD19 in an amount effective to treat the disorder in the mammalian subject; the antibody or antigen-binding fragment comprising a heavy chain variable region amino acid sequence as set forth in SEQ ID NO:29 with 0, 1 or 2 substitutions at the alternative positions specified in SEQ ID NO:29 relative to SEQ ID NO:9 and a light chain variable region amino acid sequence as set forth in SEQ ID NO:30 with 1 or 2 substitutions at the alternative positions specified in SEQ ID NO:30 relative to SEQ ID NO:17, one of which is position L83 by Kabat numbering is occupied by V; wherein the antibody or antigen-binding fragment binds to CD19 with a dissociation constant of 1.times.10.sup.-7 M; wherein the CD19-associated disorder is a CD19-expressing cancer or an immunological disorder characterized by activated immune cells expressing CD19. 2. The method of claim 1, wherein the CD19-associated disorder is a CD19 expressing cancer. 3. The method of claim 1, wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:9. 4. The method of claim 1, wherein the light chain variable region has the amino acid sequence of SEQ ID NO:24. 5. The method of claim 1, wherein the antibody comprises a human IgG constant region and is administered. 6. The method of claim 5, wherein the isotype of the IgG constant region is IgG1, IgG2, or IgG1V1. 7. The method of claim 1, wherein the antibody or antigen-binding fragment is conjugated to an anti-tubulin agent. 8. The method of claim 7, wherein the anti-tubulin agent is an auristatin. 9. The method of claim 1, wherein the antibody or antigen-binding fragment is a ligand-drug conjugate compound, wherein the ligand drug conjugate compound is of the following formula: L-(LU-D).sub.p (I) or a pharmaceutically acceptable salt or solvate thereof; wherein: L is a ligand unit wherein the ligand unit is the antibody or antigen-binding fragment; and (LU-D) is a Linker unit-Drug unit moiety, wherein: LU- is a Linker unit, and -D is a Drug unit having cytostatic or cytotoxic activity against the target cells; and p is an integer from 1 to about 20. 10. The method of claim 9, wherein the drug unit has the formula D.sub.E, D.sub.F or D.sub.Z: ##STR00037## or a pharmaceutically acceptable salt or solvate form thereof; wherein, independently at each location: R.sup.2 is C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, or C.sub.2-C.sub.20 alkynyl; R.sup.3 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, carbocycle, --C.sub.1-C.sub.20 alkylene (carbocycle), --C.sub.2-C.sub.20 alkenylene(carbocycle), --C.sub.2-C.sub.20 alkynylene(carbocycle), aryl, --C.sub.1-C.sub.20 alkylene(aryl), --C.sub.2-C.sub.20 alkenylene(aryl), --C.sub.2-C.sub.20 alkynylene(aryl), heterocycle, --C.sub.1-C.sub.20 alkylene(heterocycle), --C.sub.2-C.sub.20 alkenylene(heterocycle), or --C.sub.2-C.sub.20 alkynylene(heterocycle); R.sup.4 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, carbocycle, --C.sub.1-C.sub.20 alkylene (carbocycle), --C.sub.2-C.sub.20 alkenylene(carbocycle), --C.sub.2-C.sub.20 alkynylene(carbocycle), aryl, --C.sub.1-C.sub.20 alkylene(aryl), --C.sub.2-C.sub.20 alkenylene(aryl), --C.sub.2-C.sub.20 alkynylene(aryl), heterocycle, --C.sub.1-C.sub.20 alkylene(heterocycle), --C.sub.2-C.sub.20 alkenylene(heterocycle), or --C.sub.2-C.sub.20 alkynylene(heterocycle); R.sup.5 is H or C.sub.1-C.sub.8 alkyl; or R.sup.4 and R.sup.5 jointly form a carbocyclic ring and have the formula --(CR.sup.aR.sup.b).sub.s-- wherein R.sup.a and R.sup.b are independently H, C.sub.1-C.sub.20 alkyl, C.sub.2.sup.-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, or carbocycle and s is 2, 3, 4, 5 or 6, R.sup.6 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, or C.sub.2-C.sub.20 alkynyl; R.sup.7 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, carbocycle, --C.sub.1-C.sub.20 alkylene (carbocycle), --C.sub.2-C.sub.20 alkenylene(carbocycle), --C.sub.2-C.sub.20 alkynylene(carbocycle), aryl, --C.sub.1-C.sub.20 alkylene(aryl), --C.sub.2-C.sub.20 alkenylene(aryl), --C.sub.2-C.sub.20 alkynylene(aryl), heterocycle, --C.sub.1-C.sub.20 alkylene(heterocycle), --C.sub.2-C.sub.20 alkenylene(heterocycle), or --C.sub.2-C.sub.20 alkynylene(heterocycle); each R.sup.8 is independently H, OH, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, --O--(C.sub.1-C.sub.20 alkyl), --O--(C.sub.2-C.sub.20 alkenyl), --O--(C.sub.1-C.sub.20 alkynyl), or carbocycle; R.sup.9 is H, C.sub.1-C.sub.20 alkyl, C.sub.2.sup.-C.sub.20 alkenyl, or C.sub.2- C.sub.20 alkynyl; R.sup.24 is aryl, heterocycle, or carbocycle; R.sup.25 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, carbocycle, --O--(C.sub.1-C.sub.20 alkyl),--O--(C.sub.2-C.sub.20 alkenyl), --O--(C.sub.2-C.sub.20 alkynyl), or OR.sup.18 wherein R.sup.18 is H, a hydroxyl protecting group, or a direct bond where OR.sup.18 represents .dbd.O; R.sup.26 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, or C.sub.2-C.sub.20 alkynyl, aryl, heterocycle, or carbocycle; R.sup.10 is aryl or heterocycle; Z is O, S, NH, or NR.sup.12, wherein R.sup.12 is C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, or C.sub.2-C.sub.20 alkynyl; R.sup.11 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, carbocycle, --C.sub.1-C.sub.20 alkylene (carbocycle), --C.sub.2-C.sub.20 alkenylene(carbocycle), --C.sub.2-C.sub.20 alkynylene(carbocycle), aryl, --C.sub.1-C.sub.20 alkylene(aryl), --C.sub.2-C.sub.20 alkenylene(aryl), --C.sub.2-C.sub.20 alkynylene(aryl), heterocycle, --C.sub.1-C.sub.20 alkylene(heterocycle), --C.sub.2-C.sub.20 alkenylene(heterocycle), --C.sub.2-C.sub.20 alkynylene(heterocycle) --(R.sup.13O).sub.m--R.sup.14, or --(R.sup.13O).sub.m--CH(R.sup.15).sub.2; m is an integer ranging from 1-1000; R.sup.13 is C.sub.2-C.sub.20 alkylene, C.sub.2-C.sub.20 alkenylene, or C.sub.2-C.sub.20 alkynylene; R.sup.14 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, or C.sub.2-C.sub.20 alkynyl; each occurrence of R.sup.15 is independently H, COOH, --(CH.sub.2).sub.n--N(R.sup.16).sub.2, --(CH.sub.2)--SO.sub.3H, --(CH.sub.2).sub.n--SO.sub.3--C.sub.1-C.sub.20 alkyl, --(CH.sub.2).sub.n--SO.sub.3--C.sub.2-C.sub.20 alkenyl, or --(CH.sub.2).sub.n--SO.sub.3--C.sub.2-C.sub.20 alkynyl; each occurrence of R.sup.16 is independently H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl or --(CH.sub.2).sub.n--COOH; n is an integer ranging from 0 to 6; R.sup.27 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, O--(C.sub.1-C.sub.20 alkyl), --O--(C.sub.2-C.sub.20 alkenyl), --O--(C.sub.2-C.sub.20 alkynyl), halogen, --NO.sub.2, --COOH, or --C(O)OR.sup.28 wherein R.sup.28 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl, aryl, heterocycle, --(CH.sub.2CH.sub.2O).sub.r--H, --(CH.sub.2CH.sub.2O).sub.r--CH.sub.3, or --(CH.sub.2CH.sub.2O).sub.r--CH.sub.2CH.sub.2C(O)OH; wherein r is an integer ranging from 1-10; and X is --(CR.sup.29.sub.2).sub.I-- wherein R.sup.29 is H, C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.20 alkynyl and I is an integer ranging from 0 to 10; wherein said alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynyklene, aryl, carbocyle, and heterocycle radicals, whether alone or as part of another group, are optionally substituted. 11. The method of claim 10, wherein the ligand-drug conjugate compound has the formula, ##STR00038## or a pharmaceutically acceptable salt or solvate form thereof, wherein L is the antibody or antigen-binding fragment thereof and p is from 1 to 8. 12. The method of claim 2, wherein the CD19 expressing cancer is chronic leukemia, lymphoma, or multiple myeloma. 13. A method for treating a subject that has a CD19- expressing cancer that is refractory to treatment with rituximab comprising administering to the subject an antibody or antigen binding fragment that specifically binds to human CD19 in an amount effective to treat the disorder in the mammalian subject; the antibody or binding fragment comprising a heavy chain variable region amino acid sequence as set forth in SEQ ID NO:29with 0, 1 or 2 substitutions at the alternative positions specified in SEQ ID NO: 29 relative to SEQ ID NO:9 and a light chain variable region amino acid sequence as set forth in SEQ ID NO:30 with 1 or 2 substitutions at the alternative positions specified in SEQ ID NO:30 relative to SEQ ID NO:17, one of which is position L83 by Kabat numbering is occupied by V; wherein the antibody or antigen-binding fragment binds to CD19 with a dissociation constant of 1.times.10.sup.-7 M. 14. A method for treating a subject that has a hematological malignancy comprising administering to the subject administering an antibody or antigen binding fragment that specifically binds to human CD19 in an amount effective to treat the disorder in the mammalian subject; the antibody or binding fragment comprising a heavy chain variable region amino acid sequence as set forth in SEQ ID NO:29 with 0, 1 or 2 substitutions at the alternative positions specified in SEQ ID NO:29 relative to SEQ ID NO:9 and a light chain variable region amino acid sequence as set forth in SEQ ID NO:30 with 1 or 2 substitutions at the alternative positions specified in SEQ ID NO:30 relative to SEQ ID NO:17, one of which is position L83 by Kabat numbering is occupied by V; wherein the antibody or antigen-binding fragment binds to CD19 with a dissociation constant of 1.times.10.sup.-7 M. 15. The method of claim 14, wherein the hematological malignancy is non-Hodgkin's lymphoma or acute lymphoblastic leukemia.

Details for Patent 9,073,993

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2021-05-17
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2021-05-17
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2021-05-17